Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. India
  4. NSE India Stock Exchange
  5. HDFC Bank Limited
  6. News
  7. Summary
    HDFCBANK   INE040A01034


End-of-day quote. End-of-day quote NSE India Stock Exchange - 06/17
1466.1 INR   -1.25%
06:13aHDFC BANKá : Opens 7 New Branches in Rajasthan
01:49aHDFC Bank to Acquire 5% of HDFC ERGO General Insurance from Parent
01:29aHDFC BANKá : Declares Dividend for FY21
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Indian shares end lower as banks drop; pharma shines

09/18/2020 | 06:51am EDT

BENGALURU, Sept 18 (Reuters) - Indian shares gave up early gains to end lower on Friday as banking stocks fell in afternoon trading, with HDFC Bank closing at a month's low, although a jump in pharma stocks capped losses on the Nifty.

The blue-chip NSE Nifty 50 index closed 0.1% lower at 11,504.95, while the benchmark S&P BSE Sensex, which has fewer pharma components, ended down 0.34% at 38,845.82.

The Nifty ended the week 0.4% higher, while the Sensex closed a tad lower.

The Nifty Bank Index finished 1.3% lower at its worst closing level in a month, capping its third straight week of losses, dragged by a 2.4% slide in top private-sector lender HDFC Bank.

The Nifty Pharma index clocked its best day since Aug. 10, closing up 5%, as drugmaker Dr.Reddy's Laboratories Ltd added 10.5% to close at a record high.

The pharmaceutical firm settled a patent litigation with U.S. drugmaker Bristol-Myers Squibb Co over the cancer treatment Revlimid, prompting analyst upgrades to its stock.

Drugmakers Lupin Ltd and Cipla Ltd jumped 4.7% and 7.3%, respectively, after U.S.-listed Perrigo Company Plc issued a U.S. nationwide recall of its albuterol sulfate inhalation aerosol product due to complaints of clogging issues.

Cipla and Lupin have their own versions of the aerosol product approved by the U.S. FDA.

Investor sentiment in broader markets was also tepid on worries over a resurgence in coronavirus cases and disappointment that central banks merely affirmed their monetary support this week, without promising new stimulus. (Reporting by Anuron Kumar Mitra in Bengaluru; Editing by Ramakrishnan M.)

ę Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
CIPLA LIMITED -0.08% 960.15 Delayed Quote.17.19%
DR. REDDY'S LABORATORIES LIMITED -0.07% 5284.6 End-of-day quote.1.55%
HDFC BANK LIMITED -1.25% 1466.1 End-of-day quote.2.07%
LUPIN LIMITED -0.47% 1157.15 End-of-day quote.18.48%
NIFTY 50 0.40% 15746.5 Delayed Quote.12.17%
NIFTY BANK -0.14% 34871.3 Delayed Quote.10.54%
SENSEX 30 0.44% 52574.46 Real-time Quote.9.62%
All news about HDFC BANK LIMITED
06:13aHDFC BANKá : Opens 7 New Branches in Rajasthan
01:49aHDFC Bank to Acquire 5% of HDFC ERGO General Insurance from Parent
01:29aHDFC BANKá : Declares Dividend for FY21
06/18Asian ADRs Move Sharply Lower in Friday Trading
06/18Indian Benchmarks Close on Friday with Mixed Results; Adani Ports Shares Jump..
06/18Indian shares snap four straight weeks of gains on Fed's hawkish turn
06/17India rupee sees biggest daily fall in over 2 months on hawkish Fed
06/17Indian shares cut losses as focus shifts to Fed's U.S. growth outlook
06/15Indian shares close at record highs as pandemic curbs ease, cases fall
06/15Indian shares at record highs as COVID-19 curbs ease, cases fall
More news
Sales 2021 896 B 12 079 M 12 079 M
Net income 2021 305 B 4 107 M 4 107 M
Net Debt 2021 - - -
P/E ratio 2021 26,6x
Yield 2021 0,61%
Capitalization 8 224 B 111 B 111 B
Capi. / Sales 2021 9,18x
Capi. / Sales 2022 7,94x
Nbr of Employees 120 093
Free-Float 78,2%
Duration : Period :
HDFC Bank Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HDFC BANK LIMITED
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus -
Number of Analysts
Average target price
Last Close Price 1 479,80 
Spread / Highest target -
Spread / Average Target -
Spread / Lowest Target -
EPS Revisions
Managers and Directors
Sashidhar Jagdishan Chief Executive Officer & Managing Director
Srinivasan Vaidyanathan Chief Financial Officer
Atanu Amolendu Chakraborty Chairman
Ramesh Lakshminarayanan Chief Information Officer
Santosh Haldankar Secretary, Compliance Officer & SVP-Legal
Sector and Competitors